TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQB: TSKFF) is pleased to provide an operational update on activities at its Bralorne Gold Project in British Columbia.

Key Highlights

  • Gold Production and Sales: Produced approximately 4,884 ounces of gold from 19,014 tonnes mined at an average grade of 7.99 g/t Au up to August 31, 2026. Sold 18,499 tonnes at an average grade of 8.05 g/t Au, representing 4,788 contained gold ounces. In addition, 770 ounces was sold as gold concentrate for a total of 5,558 ounces.
  • Ore Inventory: Current inventory of approximately 8,100 tonnes, supporting continued marine shipment schedules through the remainder of 2026.
  • Underground Development: Completed 2,265 metres of underground development year-to-date, comprising 1,041 metres of operating development and 1,224 metres of capital development.
  • Mustang Production and Growth: Successfully mined the Alhambra vein stopes in the upper Mustang and added new stopes to the mine plan following positive drilling results that extended the Alhambra vein. Production long-hole drilling is underway on the BK-9870 vein system, with stoping scheduled to begin by late Q3 2026.
  • Lower Mustang Development: Advanced the Lower Mustang Decline by 329 metres in 2026, opening access to the 1045, 1030 and 1015 levels, supporting development of 13 new mineralized headings, with five currently producing and multiple additional headings planned following positive BK and Alhambra vein intercept drill results.
  • Bralorne West Development: Completed 108 metres of capital development on the Bralorne West Decline in 2025 and 296 metres in 2026 for a total of 404 metres. Constructed a resource definition drill bay at the bottom of the ramp, and commenced Phase 3 lateral development on September 3, 2026, to advance towards the centre of the Bralorne West Zone.
  • Key Underground Infrastructure: Installed and commissioned a 20-person refuge station, completed the 1045L-to-1030L ventilation raise, and progressed construction of a secondary underground explosives magazine.
  • Surface Infrastructure Expansion: Completed major earthworks and site preparation at the Mustang Mine to support future growth, including infrastructure for the crushing and sorting facility, electrical upgrades, maintenance facilities, and waste rock storage expansion.
  • Power Upgrades: Installation of a new 1.2 MW power plant with 100% redundancy is underway, with infrastructure in place to expand capacity to 2.4 MW in the future.
  • Ventilation Upgrades: Procured two 100-hp primary ventilation fans and completed associated engineering. Ventilation projects at Mustang and Bralorne West remain on schedule for commissioning in October and are expected to deliver approximately 55,000 cubic feet per minute (cfm) of additional airflow to the mine, enabling higher development and production rates.
  • Camp Expansion: Commissioned a new 32 bed accommodation facility, commenced removal and replacement of legacy camp infrastructure for a new 42 bed dormitory, mine dry, and recreation facilities.
  • Resource Conversion Drilling: Completed 26,730 metres of drilling as of August 31, 2026, including 14,933 metres at the Mustang Mine and 11,797 metres at the Bralorne West Mine. Three drill rigs remain active across the project, with plans to add a fourth drill in Q1, 2027.
  • PEA Advancement: Engineering, mine planning, and economic evaluations for the PEA are progressing and remains on schedule, with a completion date targeted for early Q4.
  • Permitting Progress: The 750 tonnes per day (tpd) permit amendment was submitted in July and is under review by governing agencies. The Company initiated work on a major joint permitting amendment for production beyond 750 tpd and construction of on-site mill. Baseline studies commenced in August 2026.
  • Crushing and Sorting Facility: Detailed engineering is progressing. Major long lead time equipment including the jaw crusher, vibrating screen plant and cone crusher have started to arrive, site earthworks preparation is underway, and construction activities are scheduled to accelerate through Q4 2026.

Terry Harbort, CEO of Talisker, commented, “Congratulations to the Talisker team for successful execution on what has been a very busy year at Bralorne. A focused and combined effort has been undertaken to build the platform for growth, with key advancement on surface infrastructure, ventilation, power, accommodation, permitting, resource conversion and most importantly development, with the opening of three new mining levels at Mustang and the completion of ramp access to our second planned mining centre at Bralorne West. With the upcoming release of our PEA, we look forward to the continued delivery of our objectives.”

Upcoming Webinar

The Company will host a webinar on Thursday, September 17, 2026, at 2:00 pm ET, during which management will review the results outlined in this news release and provide an update on ongoing activities at the Bralorne Gold Project.

Please register here: https://us02web.zoom.us/webinar/register/WN_Rd2ilciTQxqA-rgolzhHnA

The webinar livestream replay will also be available after the event: https://bit.ly/adcap-youtube.

Mining Operations

As of August 31, 2026, Talisker has achieved the following year-to-date operating results:

  • 19,014 tonnes mined at an average grade of 7.99 g/t gold, producing approximately 4,884 ounces of gold,
  • 20,644 tonnes delivered to the Company’s crushing facilities in Lillooet, including approximately 1,137 tonnes of mineralized material mined at the end of 2025,
  • 18,499 tonnes sold at an average grade of 8.05 g/t gold, representing approximately 4,788 ounces of contained gold.

At the Mustang Mine, year-to-date mining activities include:

  • Successful extraction of the Alhambra stopes between the 1090 and 1120 Levels, located within the upper Mustang Mine Zone.
  • Recent diamond drilling results identified additional mineralized material on the western extension of the Alhambra vein, resulting in the addition of new stopes to the mine plan that were not previously forecast. These stopes are expected to be mined following completion of lateral development on the 1105 and 1120 Levels.
  • In parallel, production long-hole drilling of the BK-9870 vein network in the upper Mustang Mine is currently underway, with stope extraction scheduled to commence in late Q3 2026 (Figure 3).
  • Ore production continues from active on-vein lateral development on the 1060, 1045, 1030, and 1015 Levels. This production is supplemented by high-grade material from legacy mining areas in the upper Mustang, supporting overall production and grade performance.
  • Continued advancement of the Lower Mustang Decline has totaled 329 metres in 2026, providing access to the 1045, 1030 and 1015 Levels, with development now progressing toward the 1000 Level.
  • Decline development in 2026 provided access to 13 new mineralized headings, with five currently in production, two additional headings planned on the 1015 Level following encouraging results from the BK Vein, and two Alhambra Vein extensions planned on the 1105 and 1120 Levels based on positive drill results.
  • Phase 1 and Phase 2 of the Bralorne West Access Decline were completed in 2026, consisting of 296 metres of capital development that extended underground access to the Bralorne West Zone. Subsequent work included construction of an underground diamond drill bay to support resource definition drilling. Phase 3 commenced on September 3, 2026, advancing capital development toward the centre of the Bralorne West Zone, the Black Bird ventilation raise, and future ore headings on the 1060 Level.
  • Other key work completed underground includes:
    • Installation and commissioning of a 20 person refuge station in the Bralorne West Decline;
    • Completion of a ventilation raise connecting the 1045L and 1030L levels at the Mustang Mine;
    • Development of a secondary underground explosives magazine, which will be completed by mid-October.

Table 1: Year to Date Mine Operations Metrics

Description Lateral Metres Tonnes
Lateral Development OPEX 1,041 18,477
Lateral Development CAPEX 1,224 59,811
TOTAL 2,265 86,381
Mined Ore – Lateral – 12,452
Mined Ore – Stoping – 6,604
Mined Ore – Legacy – 920
TOTAL   19,976

Talisker continues to accumulate material at its crushing and storage facility in Lillooet, British Columbia, in preparation for its next scheduled shipment. The Company currently has stockpiles totaling 7,606 tonnes, including:

  • 7,091 tonnes grading 6.54 g/t gold of crushed mineralized material
  • 515 tonnes grading 5.68 g/t gold of uncrushed mineralized material

Trucking operations from the Lillooet crushing facility to the Pembina Port of North Vancouver are ongoing, and the Company anticipates its next marine shipment will depart in late October or early November 2026.

Table 2: Bralorne Gold Project 2026 Crushing, Shipping and Stockpile Metrics.
*Differences in the totals are rounding errors.

Description Tonnes (wmt) Gold Grade (g/t Au) Gold Ounces Mined
First Marine Vessel Shipment 10,944 8.71 3,064
Current Lillooet Stockpile 6,284 6.00 1,212
Current Pembina Stockpile 807 10.77 279
TOTAL 18,035 7.86 4,558*
Uncrushed Lillooet Stockpile 515 5.68 94


Capital and Surface Infrastructure Projects

Mustang Surface Earthworks

Talisker continued investing in critical site infrastructure to support future production growth. At the Mustang Mine, clearing, grading, and earthworks commenced to expand the portal area and prepare for several major infrastructure projects. A new laydown and storage pad was completed to support the storage of supplies and equipment. The expanded site footprint will accommodate:

  • Upgrades to the waste rock storage facility with a water diversion non-contact ditch, a contact water ditch and a contact water catchment pond;
  • Adjustments to the Mustang Mine Road to accommodate space for the Crushing and Sorting Facility;
  • Planned electrical infrastructure upgrades;
  • Construction of a new heavy duty equipment maintenance facility; and
  • The sorting facility foundation.

Electrical Upgrades

Construction is underway to upgrade site electrical infrastructure to support long term mining power requirements. A 1.2MW diesel power generator with 100% redundancy is currently being installed along with 5kV site distribution to enable continuous electrical power supply for underground development and production. Infrastructure will be pre-installed to allow for an additional 1.2MW to bring the total power availability to 2.4MW with redundancy when required. Commissioning is planned to be complete by the end of September.

Ventilation

Engineering design and procurement of two 100-horsepower primary ventilation fans, together with the associated steel fan support structure, were completed during 2026. Installation and commissioning at the Mustang Mine portal are planned for Q3 and represent a key component of the Company’s long term ventilation strategy. Once operational, the fan installation and associated ducting network are expected to significantly increase ventilation capacity into both the Mustang and Bralorne West mines, supporting higher development and production rates while improving current underground operating conditions.

Within the Lower Mustang Zone, ventilation infrastructure was further advanced through the completion of the 1045L to 1030L ventilation raise and the 1030L ventilation bulkhead. These key infrastructure components allow fresh air to be delivered directly to active mining faces on the 1045L, 1030L, and 1015L, as well as the Lower Mustang Decline, currently advancing toward the 1000L Level. This improved ventilation network is expected to increase face availability, enhance operational flexibility, and allow air to be delivered further along strike, providing the ability to extend sill development should mineralization continue beyond the current mine design.

At the Bralorne West Mine, progress on the Bralorne West Decline ventilation upgrade remains on schedule, with three of five key project stages completed during Q3. Installation of the hardline ducting network began in early September, and commissioning is expected in late October following completion of the Mustang Mine power upgrades. The upgraded system is designed to provide approximately 55,000 cfm of airflow, enabling continued advancement of the Bralorne West Decline and will support development access to the mineralized zones in the Bralorne West zone.

Camp Infrastructure

Significant progress was also achieved in workforce accommodation infrastructure in 2026. Talisker successfully installed and commissioned a new 32 bed accommodation facility in Q2. Demolition of legacy camp facilities commenced in Q3 to make way for a new mine dry and shower facility, a 42 bed dormitory, a modern kitchen and recreation complex and a new mine dry facility. Installation is scheduled for the third and fourth quarters.

Capital and Infrastructure Project Investments, 2026

To date, Talisker has invested $13.4 million on capital infrastructure projects in 2026. Collectively, these investments in both surface and underground mine infrastructure and workforce accommodations strengthen the operational foundation required to support increased mining rates, future production growth, and long term value creation at the Bralorne Gold Project. 

Geology and Resource Definition Activities

Geological activities in 2026 focused on delineation drilling, underground mapping, underground grade control sampling, stockpile sampling, geological interpretation, and resource modelling across several key mineralized zones, including:

Mustang Mine

  • Alhambra Vein
  • BK Vein
  • BK-9870 Vein
  • M1 Vein

Bralorne West Mine

  • 101 Vein
  • 276 Vein
  • 277 Vein
  • 278 Vein
  • 55HW Vein
  • 55 Vein

26,730 metres of resource conversion drilling have been completed as of August 31, 2026, including 14,933 metres in the producing Mustang Main Zone and 11,797 metres in the developing Bralorne West Zone. The Company currently has three diamond drills operating across the project, with drilling focused on resource growth, resource conversion, and supporting future mine development. A fourth diamond drill is anticipated for Q1 2027.

Preliminary Economic Assessment Technical Report

Work on the Company’s updated Preliminary Economic Assessment (“PEA”) continues to advance. Engineering, mine planning, infrastructure design, and economic evaluation activities remain on schedule, with completion of the PEA targeted as planned for late Q3 to early Q4, 2026.

The PEA is expected to provide an updated assessment of the long term development potential of the Bralorne Gold Project and support future growth planning.

Permitting Update

750 Tonne Per Day Bridge Application

The Mines Act permit amendment application, originally submitted in December 2025, underwent a comprehensive review and update to align the application with planned development. The application was significantly updated and resubmitted in July 2026. Key updates include:

  • Modernization of the Reclamation and Closure Plan;
  • Expansion of the mine plan to a five year operating horizon at 750 tonnes per day; and
  • Relocation of planned camp infrastructure.

Major Permit Amendment

In July 2026, Talisker commenced a Joint Application Permit Amendment process to amend its Mines Act Permit and Environmental Management Act permits related to air emissions and effluent discharge. The amendments are designed to facilitate production rates above 750 tonnes per day and enable the construction of a milling facility at the Bralorne Gold Project.

Baseline environmental programs that will inform this application commenced in August 2026. Development of the permitting schedule is currently underway, with submission of the application targeted for 2027.

Crushing and Sorting Facility Update

Detailed engineering for the Crushing and Sorting Facility is progressing well, with key long lead time equipment deliveries now underway. The jaw crusher, cone crusher, and vibrating screen plant have been delivered. The sprung span structures that will house the equipment will begin manufacturing shortly and will start delivering in October, and additional equipment is expected to arrive throughout the fall, including the TOMRA sorter in Q4. Site preparation and earthworks are currently underway to support facility construction this fall, marking an important project milestone.

For further information, please contact:

Lindsay Dunlop
Vice President, Investor Relations
lindsay.dunlop@taliskerresources.com
+1 647 274 8975

Qualified Person

The technical information contained in this news release has been reviewed and approved by Patrick Weaver, P.Geo., Talisker’s Chief Production Geologist, Richard Murrell, C.Eng FIMMM, Talisker’s General Manager and Hugh Boden, P.Eng, Talisker’s Senior Mine Engineer, who are Qualified Persons as defined under Canadian National Instrument 43-101, Standards of Disclosure for Mineral Projects. Mr. Weaver, Mr. Murrell, and Mr. Boden are not independent of the Company in accordance with NI 43-101.

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker’s flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is producing at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an advanced stage project with significant exploration potential from an historical high-grade producing gold mine and the Spences Bridge Project where the Company has a significant landholding in the emerging Spences Bridge Gold Belt, and several other early stage Greenfields projects.

Caution Regarding Forward Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Talisker’s current belief or assumptions as to the outcome and timing of such future events. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Talisker. Although such statements are based on reasonable assumptions of Talisker’s management, there can be no assurance that any conclusions or forecasts will prove to be accurate. In particular, the Company advises that it does not have defined mineral reserves and it has not based its production decision on a feasibility study of mineral reserves demonstrating economic and technical viability, and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit.

Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration, development and operation of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined, risks relating to variations in grade or recovery rates, risks relating to changes in mineral prices and the worldwide demand for and supply of minerals, risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks regulatory risks, including risks relating to the acquisition of the necessary licenses and permits, financing, capitalization and liquidity risks, title and environmental risks and risks relating to the failure to receive all requisite shareholder and regulatory approvals. Furthermore, historically, projects that are in production without defined mineral reserves have a much higher risk of economic and technical failure. There is no guarantee that production will proceed as anticipated or at all or that anticipated production costs will be achieved.

The forward-looking information contained in this release is made as of the date hereof, and Talisker is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Talisker Resources Ltd. 09/14: Talisker Resources Ltd. 09/14

A Media Snippet accompanying this announcement is available by clicking on this link.

ORLANDO, FL, Sept. 14, 2026 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA) a global market leader in real-time 4D/5D/6D imaging sonar technology for real-time subsea intelligence and cutting-edge diving augmented reality technology (DAVD), today reported its unaudited financial results for its fiscal third quarter ended July 31, 2026 (TQ2026).

Annmarie Gayle, CODA’s Chairman and CEO, commented: “I am pleased with our overall operating results for the third quarter of fiscal 2026. During the quarter, we delivered growth in consolidated revenue, operating income and pre-tax income compared to the third quarter of fiscal 2025, while also increasing our cash position.

These results were achieved despite a decline in revenue within our core Marine Technology Business, which continues to be affected by geopolitical instability arising from the ongoing conflict involving Iran. The resulting uncertainty has impacted procurement activity across key markets in the Middle East and Asia, regions that have historically represented an important source of opportunities for our Marine Technology products.

However, the strength of our diversified business model enabled us to offset these challenges through strong growth in our Defense Engineering Services Business and continued progress in our Acoustics Sensors and Materials Business. The quarter demonstrates both the resilience of our operating model and our ability to continue investing in strategic growth initiatives while delivering improved financial performance

The numbers shown below have been rounded to one decimal point, unless two decimal points are required for clarity. The full TQ2026 financials can be found in CODA’s Form 10-Q filed with the SEC on September 14, 2026:

  • Total revenue was approximately $7.7 million compared to $7.1 million in TQ2025, representing an increase of 9.2%.
  • Revenue from our core business (Marine Technology Business) was $3.4 million compared to $4.0 million in TQ2025, representing a 15.2% decrease.
  • Revenue from our Defense Engineering Services Business was $2.7 million compared to $1.6 million in TQ2025, representing an increase of 68.3%.
  • Revenue from the Acoustics Sensors and Material Business was $1.6 million compared to $1.5 million in TQ2025, representing an increase of 10.4%.
  • Gross profit was $5.1 million compared to $4.8 million in TQ2025. Gross margin was 65.4% compared to 68.3% in TQ2026, reflecting the mix of type and geography of sales reported in the Period.
  • Operating income was $1.5 million in TQ2026 compared to $1.4 million in TQ2025, representing an increase of 11.1%.
  • Operating margin was 19.9% compared to 19.5% in TQ2025, reflecting the increase in our gross profit in conjunction with a reduction in SG&A expenditures.
  • Pre-tax income was approximately $1.8 million in TQ2026 compared to $1.5 million in TQ2025, representing an increase of 16.0%.
  • Net income after taxes was approximately $1.4 million in TQ2026 compared to approximately $1.3 million in TQ2025, an increase of 8.3%.
  • Diluted earnings per share in TQ2026 was $0.12 compared to $0.11 in TQ2025.
  • Pre-tax income as a percentage of revenues for TQ2026 was approximately 23.2% compared to 21.9% in TQ2025. Research and Development expenditures for TQ2026 were approximately $0.7 million compared to approximately $0.6 million in TQ2025, representing an increase of 27.4%. SG&A in TQ2026 was approximately $2.8 million compared to $2.9 million in TQ2025, representing a decrease of 2.9%.

Our cash balance at the end of TQ2026 of $31.7 million representing an increase of $3.0 million over October 31, 2025, when this figure was $28.7 million.

Annmarie Gayle, CODA’s Chairman and CEO, commented: “While geopolitical instability continues to affect customer activity in certain regions, particularly the Middle East and parts of Asia, we were encouraged by the overall performance of the business during the quarter and by the increasing diversification of our revenue base.

Within our U.S. Defense Engineering Services business, we continued to see strengthening demand for repairs, sustainment and spare parts supporting long-standing U.S. defense programs. During the quarter, one of our prime contractor customers was awarded a multi-year repair and sustainment contract by the U.S. Government. Following that award, we experienced increased repair-related activity and additional subcontract opportunities associated with the program. We continue to view this area as a source of steady demand and future growth. Demand for spare parts supporting these sustainment programs also remains robust exceeding $2.4 million year-to-date.

We also continue to make progress in electronic warfare, which remains a significant area of defense investment. Our U.S. Defense Engineering Services segment is currently supporting several prime contractors in the development of rugged, deployable radio frequency (RF) electronic warfare systems for a variety of platforms, including unmanned systems, helicopters, airborne pods and ground vehicles. We believe these programs represent meaningful long-term opportunities, allowing us to build upon our established positions on legacy defense platforms while expanding into next-generation defense programs as technologies and operational requirements continue to evolve.

Within our Marine Technology business, we continue to make meaningful progress across our key strategic growth initiatives. During the quarter, we received orders totaling approximately $1.4 million for our proprietary DAVD tethered systems and peripherals. We believe our DAVD untethered system represents the larger long-term market opportunity for the DAVD technology. With Approved Navy Use authorization now in place, our customer has commenced training discrete user groups on the DAVD untethered system, and we continue to support this training program. We are also supporting several integration programs under contract where DAVD forms part of the vision and situational awareness component of broader operational systems.

We are likewise encouraged by the early market response to our recently launched Echoscope PIPE NANO Gen Series®. Customer engagement remains strong, and we are currently working with at least five customers on the integration of NANO systems into their underwater vehicle platforms.

Echoscope® products currently account for approximately 80% of Marine Technology Business revenue. The NANO Gen Series expands our addressable market by enabling smaller underwater platforms to benefit from real-time 3D spatial awareness, obstacle avoidance and enhanced situational awareness through a compact, power-efficient solution. We believe this positions us well to expand further into the growing defence, underwater robotics and autonomous vehicle markets. The technology is also complementary to our DAVD product line, with potential applications across diver-worn systems, diving platforms and a broad range of subsea robotic solutions.

We believe the long-term market drivers underlying our business remain compelling. Global defence priorities continue to focus on autonomous and unmanned maritime capabilities, creating significant opportunities for advanced underwater sensing, imaging and situational awareness technologies. Against this backdrop, we remain focused on commercial execution, innovation and expanding adoption of our key technologies while positioning the Company for long-term growth.”

The Company’s full financial results, including its results for the TQ2026, are available at www.nasdaq.com/symbol/coda/sec-filings.

Conference Call

CODA will host a conference call today, September 14, 2026, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) to discuss its results for its Fiscal Third Quarter ended July 31, 2026.

CODA management will provide prepared remarks, followed by a question-and-answer period.

Date: Monday, September 14, 2026

Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)

U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879

International number: 1-201-389-0879

Conference ID: 13762021

The conference call will broadcast live and be available for replay here.

Persons interested in attending are required to call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please press *0.

A replay of the call will be available after approximately 2:00 p.m. Eastern time on the same day through Monday, September 28, 2026 at 11:59 p.m. ET.

Telephone replay numbers: 1-844-512-2921 or 1-412-317-6671

International replay number: 1-412-317-6671

Access ID: 13762021

About Coda Octopus Group, Inc.

Coda Octopus Group, founded in 1994, is a leading provider of innovative solutions for the underwater and subsea markets. The Company develops and supplies a range of hardware and software technologies, including its proprietary real-time 4D/5D/6D imaging sonars—marketed under the Echoscope®, Echoscope PIPE®, and Echoscope PIPE NANO Gen Series® brands—and its next-generation Diver Augmented Vision Display (DAVD) system. The Echoscope PIPE® sonar produces real-time 3D/4D/5D imagery of moving objects underwater, even in zero-visibility conditions, and is used globally across commercial offshore and defense applications. These include complex underwater mapping, subsea intervention, asset placement, salvage and recovery, search and rescue, offshore renewable energy, marine construction, robotics, decommissioning, mine countermeasures, ship-hull scanning, diving operations, and port and harbor security.

The Company’s DAVD system has the potential to transform diving operations in both defense and commercial markets. DAVD integrates topside control with a diver-worn heads-up display, enabling shared visualization of the underwater environment and the exchange of critical information. By incorporating the Company’s sonar technology, DAVD also enables operations in zero-visibility conditions—a longstanding challenge in the diving industry.

Coda Octopus Group expanded its capabilities through the acquisition of Precision Acoustics Limited, a recognized leader in acoustic sensors and materials. Precision Acoustics specializes in hydrophone design and advanced acoustic materials for medical imaging and non-destructive testing (NDT), supporting the assessment of structures such as aircraft, ship hulls, wellheads, and other subsea assets. The company also collaborates with national and international standards bodies, including the UK’s National Physical Laboratory, contributing to the development of primary measurement standards.

The Group also includes two Defense Engineering Services businesses—Coda Octopus Martech Ltd (UK) and Coda Octopus Engineering, Inc. (U.S.)—which supply mission-critical sub-assemblies to major defense programs as subcontractors to prime contractors. Their work spans concept development, design, prototyping, manufacturing and post-delivery support, creating opportunities for recurring revenue throughout the life cycle of long-term defense programs

For further information, please visit http://www.codaoctopusgroup.com or contact us at coda@codaoctopusgroup.com.

Forward Looking Statements

This press release contains forward-looking statements concerning Coda Octopus Group, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “assume” and similar expressions are intended to identify forward‐looking statements. Those forward-looking statements include, without limitation, statements regarding the Company’s expectations for the growth of the Company’s operations and revenue. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, fluctuations in foreign exchange rates, changes in global economic conditions, tariff and trade policies, reductions in government defense spending, customer demand, geopolitical issues, the outcome of our ongoing research and development efforts relating to our products, including our patented real-time 3D solutions and DAVD; our ability to develop and expand the sales and business development capabilities required to commercialize our products and technologies; and other risks and uncertainties described in our Annual Report on Form 10-K for the year ended October 31, 2025, filed with the Securities and Exchange Commission on January 29, 2026, as amended by Form 10-K/A filed on February 26, 2026. Coda Octopus Group, Inc. does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:

Mr. Dillon King

Coda Octopus IR Team at coda.ir@codaoctopusgroup.com

Coda Octopus Group, Inc.

1- 407-735-2406

 CODA OCTOPUS GROUP, INC.
Consolidated Balance Sheets (Unaudited)
July 31, 2026 and October 31, 2025
 
    2026     2025  
ASSETS            
             
CURRENT ASSETS                
                 
Cash and Cash Equivalents   $ 31,714,519     $ 28,682,615  
Accounts Receivable, net     5,620,208       3,732,806  
Inventory     13,487,657       13,636,512  
Unbilled Receivables     3,260,065       2,988,779  
Prepaid Expenses     356,128       434,021  
Other Current Assets     161,128       531,469  
                 
Total Current Assets     54,599,705       50,006,202  
                 
FIXED ASSETS                
Property and Equipment, net     7,428,835       7,295,791  
Right of Use Assets     339,766       372,647  
                 
Total Fixed Assets, net     7,768,601       7,668,438  
                 
OTHER ASSETS                
Goodwill     3,639,334       3,639,334  
Intangible Assets, net     2,845,726       3,179,588  
                 
Total Other Assets     6,485,060       6,818,922  
                 
Total Assets   $ 68,853,366     $ 64,493,562  

CODA OCTOPUS GROUP, INC. 
Consolidated Balance Sheets (Unaudited)
(Continued) July 31, 2026 and October 31, 2025

   
     
    2026     2025      
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                    
                     
CURRENT LIABILITIES                    
                     
Accounts Payable   $ 977,071     $ 1,407,439      
Current portion of operating lease liabilities     42,159       34,862      
Accrued Expenses and Other Current Liabilities     2,577,220       2,475,952      
Deferred Revenue     1,829,012       1,722,796      
                     
Total Current Liabilities     5,425,462       5,641,049      
                     
LONG TERM LIABILITIES                    
Deferred Tax Liability, net     317,214       317,949      
Non-current operating lease liabilities, net     343,222       360,070      
Deferred Revenue, net     36,656       59,080      
                     
Total Long Term Liabilities     697,092       737,099      
                     
Total Liabilities     6,122,554       6,378,148      
                     
Commitments and contingencies                    
                     
STOCKHOLDERS’ EQUITY                    
                     
                     
Common Stock, $.001 par value; 150,000,000 shares authorized, 11,291,850 issued and 11,280,754 outstanding as of July 31, 2026 and 11,280,368 shares issued and 11,270,575 outstanding as of October 31, 2025     11,281       11,271      
Preferred Stock $.001 par value; 5,000,000 shares authorized, zero issued and outstanding as of July 31, 2026 and October 31, 2025     –       –      
Treasury Stock 11,096 shares as of July 31, 2026 and 9,793 at October 31, 2025     (75,602 )     (61,933 )    
Additional Paid-in Capital     63,360,347       63,321,294      
Accumulated Other Comprehensive Loss     (1,306,798 )     (1,878,657 )    
Accumulated Earnings (Deficit)     741,584       (3,276,561 )    
                     
Total Stockholders’ Equity     62,730,812       58,115,414      
                     
Total Liabilities and Stockholders’ Equity   $ 68,853,366     $ 64,493,562      

CODA OCTOPUS GROUP, INC.
Consolidated Statements of Income and Comprehensive Income (Unaudited)
 
                         
    Three Months Ended July 31,     Nine Months Ended July 31,  
    2026     2025     2026     2025  
                         
Net Revenues   $ 7,717,469     $ 7,064,795     $ 21,331,593     $ 19,291,969  
Cost of Revenues     2,667,175       2,241,039       7,336,216       6,542,462  
                                 
Gross Profit     5,050,294       4,823,756       13,995,377       12,749,507  
                                 
OPERATING EXPENSES                                
Research & Development     729,216       572,468       1,983,622       1,805,589  
Selling, General & Administrative     2,787,803       2,871,309       7,675,434       7,814,233  
                                 
Total Operating Expenses     3,517,019       3,443,777       9,659,056       9,619,822  
                                 
INCOME FROM OPERATIONS     1,533,275       1,379,979       4,336,321       3,129,685  
                                 
OTHER INCOME                                
Other Income     24,259       8,922       197,453       119,921  
Interest Income     233,817       154,848       578,002       494,613  
                                 
Total Other Income, net     258,076       163,770       775,455       614,534  
                                 
INCOME BEFORE INCOME TAX EXPENSE     1,791,351       1,543,749       5,111,776       3,744,219  
                                 
INCOME TAX (EXPENSE) BENEFIT                                
Current Tax (Expense)     (408,583 )     (268,786 )     (1,104,002 )     (692,361 )
Deferred Tax Benefit     6,844       8,022       10,371       52,864  
                                 
Total Income Tax (Expense)     (401,739 )     (260,764 )     (1,093,631 )     (639,497 )
                                 
NET INCOME   $ 1,389,612     $ 1,282,985     $ 4,018,145     $ 3,104,722  
                                 
NET INCOME PER SHARE:                                
Basic   $ 0.12     $ 0.11     $ 0.36     $ 0.28  
Diluted   $ 0.12     $ 0.11     $ 0.36     $ 0.27  
                                 
WEIGHTED AVERAGE SHARES:                                
Basic     11,279,904       11,237,654       11,275,149       11,226,665  
Diluted     11,298,951       11,304,549       11,294,196       11,293,560  
                                 
NET INCOME   $ 1,389,612     $ 1,282,985     $ 4,018,145     $ 3,104,722  
                                 
Foreign Currency Translation Adjustment     (98,810 )     70,492       571,859       842,345  
                                 
Total Other Comprehensive (Loss) Income   $ (98,810 )   $ 70,492     $ 571,859     $ 842,345  
                                 
COMPREHENSIVE INCOME   $ 1,290,802     $ 1,353,477     $ 4,590,004     $ 3,947,067  

Renowned industry expert brings proven experience in international market development and government relations

Appointment reflects Company’s commitment to building long-term leadership positions in global cannabis markets

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced the appointment of Deepak Anand as Vice President of Government Affairs. In this newly created role, Mr. Anand will lead government relations, regulatory affairs and public policy strategies across the Company’s global footprint, with a particular focus on activating new market and product growth opportunities. Mr. Anand brings close to two decades of experience at the intersection of cannabis policy, government relations and international market development, and will report directly to Chief Strategy Officer Brian Stevenson.

President and Chief Executive Officer Michael A. DeGiglio commented, “Deepak is a widely respected voice in global cannabis policy, and his appointment reflects our increasing strategic focus on developing strong international government affairs as we continue expanding around the globe. We’re proud to welcome him to Village Farms and believe his track record building relationships with regulators and policymakers across multiple continents will strengthen our ability to build long-term leadership positions in new and existing markets.”

Deepak Anand commented, “Village Farms has built one of the most attractive platforms in the global cannabis industry, and I’m excited to join a company with such strong international growth ambitions. Over the course of my career, I’ve had the opportunity to work with licensed producers, policymakers and senior government officials around the world, and I look forward to bringing that experience to the Company as we continue navigating the evolving global regulatory landscape.”

Prior to joining Village Farms, Deepak served as President of ASDA Consultancy Services, where he advised more than 40 cannabis companies globally, as well as consumer packaged goods and tobacco companies entering the cannabis industry. He also previously served as Vice President of Government Relations at Cannabis Compliance Inc. (“CCI”), a leading cannabis regulatory and compliance consulting firm later acquired by Deloitte, and as Vice President of Business Development at Zenabis. He has developed businesses across Europe, including in Germany and the United Kingdom, and has held several board and advisory roles across the global cannabis industry, including as an independent director of The Valens Company. Mr. Anand holds a Master of Business Administration from Vancouver Island University.

About Village Farms International, Inc.

Village Farms is a global leader in cannabis, plant-based consumer packaged goods, and sustainable innovation. With a legacy built on decades of Controlled Environment Agriculture expertise and Dutch farming practices, today the Company is one of the world’s largest and most profitable cannabis operators with an asset portfolio that spans over 7 million square feet of advanced greenhouse and indoor cultivation assets.

In Canada, Village Farms operates the world’s largest EU-GMP certified cannabis facility at its production campus in Delta, British Columbia, and exports products to international medical markets. The Company is also a market share leader in dried flower formats and produces and distributes some of the country’s highest quality and best-selling strains, including its flagship Pure Sunfarms Pink Kush, one of the most widely consumed strains on the planet. Village Farms’ Canadian brand portfolio includes Pure Sunfarms, Fraser Valley Weed Co., Soar, Super Toast, Pure Laine, Tam Tams and Promenade.

In the Netherlands, the Company is one of only ten licensed operators in the country’s regulated cannabis program, and in the United States its CBDistillery brand is one of the country’s premier cannabinoid wellness platforms, and it also holds equity interests in cannabis businesses in Australia and Germany. Beyond cannabis, the Company holds an equity interest in Verdexa Holdings, a private venture pursuing strategic acquisitions to build a premier branded food platform, and its Clean Energy division transforms landfill gas into renewable natural gas and receives royalties on all revenues generated.

Contact Information

Sam Gibbons
Senior Vice President, Corporate Affairs
Phone: (407) 495-5067
Email: sgibbons@villagefarms.com

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Topline overall survival data expected as early as end of 2026

(OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297).

TEBE-AM is a global, randomized, registrational Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab, versus Investigator’s Choice, for the treatment of HLA-A*02:01-positive patients with advanced melanoma whose disease has progressed following prior therapy. The primary endpoint is overall survival.

“Achieving target enrollment in TEBE-AM is an important milestone for Immunocore and a critical step toward addressing the substantial unmet need in previously treated, post-PD1 advanced melanoma, a setting with limited treatment options,” said Mohammed Dar, Chief Medical Officer of Immunocore. “We are grateful to the patients and investigators participating in the trial.”

With target enrollment now achieved, patients enrolled in the trial will continue to be followed for the planned overall survival analysis.

The Company believes tebentafusp has the potential to address a significant unmet need for up to 4,000 HLA-A*02:01-positive patients with previously treated advanced melanoma in the post-PD1 setting, in the United States and Europe. The Company expects to be able to share topline data as early as the end of 2026.

###

About ImmTAC® molecules for cancer

Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumors.

About TEBE-AM – Phase 3 registrational trial with tebentafusp in previously treated advanced melanoma

The trial is evaluating tebentafusp in patients with second-line or later advanced melanoma who have progressed on an anti-PD1, received prior ipilimumab and, if applicable, received a BRAF kinase inhibitor. The study comprises three arms: tebentafusp as monotherapy, tebentafusp in combination with an anti-PD-1, and a control arm. The primary endpoint is overall survival.

About Cutaneous Melanoma

Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related mortality. The majority of patients with CM are diagnosed before metastasis and survival remains poor for the large proportion of patients with metastatic disease. Despite recent progress in advanced melanoma therapy, there is still an unmet need for new therapies that improve first-line response rates and duration of response as well as for patients who are refractory to first-line treatments.

About KIMMTRAK®

KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore’s ImmTAC technology platform, designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

IMPORTANT SAFETY INFORMATION

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin Reactions

Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes

Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal Toxicity

KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the estimated size of the patient populations for the Company’s product candidates; the Company’s expectations regarding the design, progress, timing, enrollment, randomization, scope, expansion, and results of its TEBE-AM trial. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions, including as a result of health epidemics or pandemics, war in Ukraine, the conflict in the Middle East, or global geopolitical tension, on the Company’s business, financial position, strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; the Company’s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products; the Company’s ability to obtain and maintain regulatory approval of KIMMTRAK and its other product candidates; the Company’s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; the Company’s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; the Company’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore’s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled “Risk Factors” in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 25, 2026, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.

Contact Information

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Ryan Baker, Vice President, Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com

The Company remains materially unaffected by recently announced U.S. tariffs and procurement restrictions

MONTREAL, Sept. 14, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, confirms that, based on the information currently available and the Company’s assessment to date, recently announced U.S. tariffs and procurement restrictions are not expected to have a materially adverse impact on the Company’s operations or financial results. This update responds to investor questions concerning recent Canada-U.S. trade policy developments and the resulting tariffs and regulatory restrictions affecting certain Canadian products.

The Company continues to closely monitor the tariff environment which has changed substantially in the last few weeks after Canada suspended negotiations with respect to a potential U.S. trade agreement. Subsequent counter-tariffs were implemented by both countries. Most recently, on September 8, the U.S. government directed the General Services Administration, working with the U.S. Trade Representative, to take steps to remove Canadian-origin products from the General Services Administration’s Multiple Award Schedules (GSA MAS). GSA MAS is a procurement program through which federal agencies and other eligible government buyers may acquire commercial products and services.

Based on the Company’s assessment to date, none of these developments have materially affected PyroGenesis’ goods or operations.

Certain machinery exported by PyroGenesis to the U.S has, for several years, been subject to a 10% tariff. Based on the company’s review of the applicable tariff classifications and measures announced to date, the tariff rate applicable to that machinery has not changed

With respect to the announced U.S. federal procurement changes, PyroGenesis does not currently supply goods directly to U.S. federal agencies other than in connection with certain U.S. Department of Defense activities. Based on the information currently available to the Company, the universities and university research facilities supplied by PyroGenesis are not expected to be materially affected. Although GSA MAS is principally used by federal agencies, state and local governments and certain other eligible entities (such as public universities, that are governed at the state level) may acquire specified products and services through the program; accordingly, the effect on any institution should be assessed based on its eligibility, funding source and procurement requirements.

Additionally, it is understood by the Company that defense-related clients, especially those connected to U.S. federal funding agencies, operate under specific regulatory exceptions and statutory carve-outs that legally allow or require contracting officers to deviate from or look outside of GSA Schedules, in the interest of national security.

Finally, it is important to note that the Company maintains the capability to manufacture and assemble its systems in Canada, the United States, and other jurisdictions worldwide. This flexibility reduces reliance on any single geographic location and enables the Company to respond efficiently to changing market conditions, customer requirements, and supply chain considerations. In the event of changes to U.S. tariff policies or other trade measures, the Company’s diversified supply chain and global manufacturing capabilities provide the flexibility to adjust sourcing, manufacturing, and assembly activities as appropriate to mitigate potential impacts and continue serving customers efficiently.

“Based on the information currently available, I am confident that the recently imposed tariffs and procurement restrictions will have little to no direct negative impact on PyroGenesis,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “We will continue to closely monitor the situation, but for now, we can safely say that PyroGenesis has positioned itself in such a way that these recent announcements will not change our situation.”

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

  • Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people.
  • K Env is found in the spinal fluid of more than 75% of people with ALS and has been shown to produce the neurodegenerative findings of ALS in experimental animals and human neuron cells.
  • The patent (EP 3 570 878 B1) covers a novel monoclonal antibody (GNK-301) developed by GeNeuro and scientists at the US National Institute of Neurological Disorders and Stroke (NINDS) under a Cooperative Research and Development Agreement and co-owned under a subsequent patent agreement. Two US patents (10,723,787 and 10,981,977) have previously been granted for this invention.
  • As described in the patents, GNK-301 has been shown to prevent the neurotoxic effects of K Env in nonclinical subjects and in human motor neuron cells – the cells that are damaged by ALS.
  • GeNeuro has instituted GMP manufacture of GNK-301 and anticipates initiating human Phase I trials in patients with ALS in the second half of 2027 in the US and Europe.
  • GeNeuro was selected in the first round of the Congressionally Directed Medical Research Program for two potential awards and is finalizing its submission.
  • GeNeuro will participate in a conference this weekend on “HERVs and Humanity” bringing together leading clinicians and molecular biologists to focus on the understanding and treatment of HERV-induced diseases, including ALS, Multiple Sclerosis, Optic Neuritis, and Schizophrenia.

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) — GeNeuro, Inc., (“GeNeuro” or the “Company”), a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced the award of a European Patent (EP 3 570 878 B1) entitled “Anti HERV K Envelope Antibody and Uses Thereof.” The patent, together with two previously-issued US patents (10,723,787 and 10,981,977) describes in detail the discovery that the envelope protein (K Env) of Human Endogenous Retrovirus K (HERV K) is found in the spinal fluid of more than 75% of people with Amyotrophic Lateral Sclerosis (ALS), is shown to be highly neurotoxic, and to produce the neurodegenerative findings of ALS in laboratory animals and in human motor neuron cell culture.

HERVs are the remnants of viruses that infected primates between 2 and 5 million years ago and are now thought to have played a role in human disease. A monoclonal antibody against K Env (GNK-301) has been shown to block those neurotoxic effects in the same models. The discovery was made by a team comprised of scientists from Geneuro SA (Lyon, France) and the US National Institute of Neurological Disorders and Stroke (NINDS) of the US National Institutes of Health (NIH) under a Cooperative Research and Development Agreement (CRADA) and subsequent patent agreement. The patents are jointly owned by GeNeuro and the US Dept. of Health and Human Services.

The assets of the former Geneuro SA were awarded to GeNeuro, Inc. (Miami, FL) by the Courts of Switzerland in June 2026 and GeNeuro initiated manufacture of GNK-301 under Good Manufacturing Practices (cGMP) with the plan to initiate human Phase 1 trials of GNK-301 in the US and Europe in the latter half of 2027.

Geneuro SA previously conducted five human trials of a related antibody (Temelimab®) which targets the envelope protein of HERV W in more than 400 human participants who had Multiple Sclerosis, Type 1 Diabetes, or symptoms of Long Covid, with no Serious Adverse Events. Temelimab was shown to cross the blood brain barrier and to achieve a statistically significant reduction in neurodegeneration, as measured by “Black Holes” on Magnetic Resonance Imaging (MRI) and a corresponding reduction in brain shrinkage. The Company believes these results support the potential for anti-HERV Envelope antibodies to achieve clinically meaningful effects in patients with HERV-mediated neurodegenerative diseases.

The recently-issued patent adds to a portfolio of more than 25 issued and pending patents owned by GeNeuro related to the effects of HERVs and to methods of diagnosing and mitigating those effects. A more comprehensive list can be found on www.geneuro.us.

In August 2026, GeNeuro, in partnership with NINDS was selected in the first round of the ALS grant competition of the Congressionally Directed Medical Research Program (CDMRP) for potential awards in Therapeutic Development and Biomarker Development and is currently preparing its final bid submission. This weekend, the first annual conference on “HERVs and Humanity” will be held at the Princeton Institute for Advanced Study to bring together an international group of clinicians and molecular biologists to prioritize research objectives and clinical priorities in this dramatic new area of science. Portions of the conference will be simulcast.

“ALS is possibly the most devastating diseases one can contract, with a life expectancy of two to five years. The opportunity to partner with the NIH and leading experts across the globe around a biomarker-targeted, potentially disease-modifying drug has the potential to forever change the course of this terrible disease,” said Dr. Jonathan Javitt, the Company’s CEO.

About GeNeuro, Inc.

GeNeuro, Inc. (www.geneuro.us) is a newly-formed US Company organized around the assets of the former Geneuro SA. Those assets include the products of more than $180 million in funded research on Human Endogenous Retrovirus-targeted drugs for ALS, Multiple Sclerosis, Type 1 Diabetes, and Schizophrenia. Temelimab, targeting the HERV W Envelope protein has reached Phase 2 in Europe with completed clinical trials demonstrating statistically-significant reductions in neurodegeneration in multiple sclerosis and decreased Islet cell destruction in Type 1 diabetes. GNK-301, targeting ALS was developed and patented worldwide under a Cooperative Research and Development Agreement with the US National Institutes of Health and is now in production and anticipated to enter Phase 1 human trials in the second half of 2026.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in NRx Pharmaceuticals, Inc.’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Brian Korb Matthew Duffy
Managing Partner, astr partners Chief Business Officer
(917) 653-5122 +1 (646) 335-5923
brian.korb@astrpartners.com mduffy@geneuro.us

FREEHOLD, NJ, Sept. 14, 2026 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in the ownership and operation of manufactured home communities, today announced that the Company will attend the U.S. Department of Housing and Urban Development’s (HUD) annual Innovative Housing Showcase for the 6th consecutive year. The event kicks off with the Showcase Opening Ceremony on Tuesday, September 22, 2026, on the National Mall in Washington, D.C. and runs through Thursday, September 24, 2026.

Samuel A. Landy, President and Chief Executive Officer, commented, “At this year’s Innovative Housing Showcase, UMH is proud to present two ground-breaking manufactured homes in partnership with Champion Homes and Cavco Industries. Making its debut on the National Mall is the first-ever HUD-code two-story manufactured home built by Champion Homes. This three-bedroom, two-bath home showcases the evolution of modern manufactured housing through this innovative design. UMH will also feature an off-frame, two-bedroom, two-bath multi-section home built by Cavco Industries, demonstrating the removal of the traditional chassis and highlighting the construction advancements shaping the future of manufactured housing. Together, these homes expand the possibilities of high-quality affordable housing. This event provides policymakers and the public with an opportunity to experience these homes firsthand, and we invite everyone to attend it.”

UMH Properties, Inc., which was organized in 1968, is a public equity REIT that currently owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,200 contain rental homes, and over 1,000 self-storage units. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina, Florida and Georgia. Included in the 145 communities are two communities in Florida, containing 363 sites, and one community in Pennsylvania, containing 113 sites, that UMH has an ownership interest in and operates through its joint ventures with Nuveen Real Estate.

Contact: Nelli Madden

732-577-4062

Wilmington, Del., Sept. 14, 2026 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) will host an Innovation Day webcast on September 17, 2026. The event will begin promptly at 9:00 am ET and conclude by 11:00 am ET. Ashland leadership will provide an updated overview of the company’s innovative Technology Platforms, highlighting their commercial progress and scalability.  Registration is required, and participants are encouraged to join early. Registration can be accessed from the following link:  https://innovationday26.ashland.com

During the event, participants will hear from Ashland executives and senior technology leaders as they provide an in-depth review of the latest innovations and expanding commercial opportunities. The presentations will detail how these advancements are poised to impact key markets and drive organic growth.

Following the formal remarks, participants will have the opportunity to engage directly in a moderated question-and-answer (Q&A) session.

Ashland leaders presenting at the event include:

  • Guillermo Novo, chair, and chief executive officer
  • Osama Musa, senior vice president and chief technology officer
  • Jim Minicucci, senior vice president and general manager, personal care
  • Alessandra Faccin, senior vice president and general manager, life sciences and intermediates
  • Dago Caceres, senior vice president and general manager, specialty additives
  • William Whitaker, senior vice president and chief financial officer
  • Sandy Klugman, director, investor relations

Registration information and further event details can be found on Ashland’s investor website at http://investor.ashland.com

A webcast of the event will be available live and can be accessed, along with supporting materials, through the Ashland website. A replay will be available within 24 hours of the live event and will be archived, along with supporting materials, on the Ashland website for 12 months. Copies of the presentation may also be requested by sending an email to investor_relations@ashland.com

About Ashland 
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.  

™ Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Media Relations:
Sandy Klugman Carolmarie C. Brown
+1 (302) 594-7777 +1 (302) 995-3158
sandy.klugman@ashland.com ccbrown@ashland.com

Attachment

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time.

A live webcast of the fireside chat can be accessed through the Investors section of the Company’s website at www.lyell.com. A replay of the webcast will be available on the Company’s website following the event.

About Lyell Immunopharma, Inc.

Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s proprietary LyFE Manufacturing Center™ has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact:

Lyell Investor Relations
IR@lyell.com

Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity

HIGHLIGHTS

  • Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development
  • Positioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangements
  • Designed to coordinate supply, manufacturing, regulatory and potential clinical development activities through a single U.S. entity with U.S.-based partners

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, today announced the formation of Texas Ibogaine Research Corporation (“TIRC”), a Texas-based company established to coordinate the Company’s U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development.

TIRC has been established as the Company’s dedicated U.S. vehicle for the regulated development of ibogaine. Subject to completion of definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, a neuroplastogen active pharmaceutical ingredient development company in which Psyence BioMed holds an ownership interest.

The Company intends for TIRC to coordinate the applicable rights, manufacturing arrangements, regulatory documentation and any future investigational new drug application within a single U.S. entity financed by Psyence BioMed. TIRC is also intended to serve as the Company’s counterparty of record in engagements with federal agencies, state programs and potential clinical partners in the United States.

Jody Aufrichtig, Chief Executive Officer of Psyence BioMed, will also serve as Chief Executive Officer of TIRC. Dr. John Thorne has been appointed project lead. Psyence BioMed expects to provide technical, legal, administrative and financial support through existing internal resources, with corporate oversight that includes Chief Financial Officer Warwick Corden-Lloyd and the Company’s in-house legal function.

“The United States is creating new momentum around rigorous, regulated ibogaine research. We established TIRC in Texas to contribute to that effort by bringing the rights, pharmaceutical-grade supply and development strategy together within a dedicated U.S. company advancing this research for U.S. patients.”

— Jody Aufrichtig, Chief Executive Officer, Psyence BioMed and Texas Ibogaine Research Corporation

“TIRC gives us a focused structure through which to coordinate the material, regulatory documentation, manufacturing pathway and clinical development plan. This positions us to engage efficiently with government agencies and potential research partners as opportunities advance.”

— Dr. John Thorne, Project Lead, Texas Ibogaine Research Corporation

The formation of TIRC follows a series of U.S. policy and research developments involving neuroplastogens, including ibogaine. These include the Executive Order signed on April 18, 2026, directing federal agencies to accelerate relevant research; the coordinated federal implementation announced in July 2026; and the subsequent provision to the U.S. Department of Health and Human Services of the University of Miami’s original 1994 ibogaine investigational new drug application.

Psyence BioMed intends to provide further updates as TIRC advances its licensing, manufacturing, regulatory and potential clinical development activities. Expected next steps include completing definitive licensing arrangements, progressing regulatory engagement and developing the manufacturing and clinical plans required to support a potential U.S. development program. These activities remain subject to applicable laws, regulatory requirements and the availability of appropriate development pathways.

ABOUT PSYENCE BIOMED

Psyence Biomedical Ltd. (Nasdaq: PBM) is a life sciences biotechnology company developing nature-derived neuroplastogen therapeutics. Through its multi-asset development platform and supply capabilities, the Company is advancing pharmaceutical-grade psilocybin- and ibogaine-based development programs using an evidence-based approach. Psyence BioMed is focused on addressing unmet needs in mental health and substance-use disorders through the development of safe, effective and regulator-approved treatments. Its U.S. subsidiary, Texas Ibogaine Research Corporation, is headquartered in Texas.

ABOUT PSYLABS

PsyLabs is an international neuroplastogen active pharmaceutical ingredient development company federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. PsyLabs operates from an ISO 22000 and GMP-compliant facility, with a focus on natural compound purification, regulatory support and global distribution. www.psylabs.life

CONTACTS

Psyence Biomedical Ltd. · ir@psyencebiomed.com · media@psyencebiomed.com · info@psyencebiomed.com · +1 416-477-1708

Investor contact: Michael Kydd, Investor Relations Advisor — michael@psyencebiomed.com 

FORWARD-LOOKING STATEMENTS

This communication contains “forward-looking statements” within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995. These include statements regarding the intended role, financing and activities of TIRC; the execution, scope and duration of definitive licensing arrangements with PsyLabs; TIRC’s expected ownership of U.S. rights to pharmaceutical-grade ibogaine; the Company’s ability to obtain and maintain required registrations, permits, quotas and licenses; its ability to participate in federal or state ibogaine programs; and its expected role in future research, development and commercialization activities relating to ibogaine. Forward-looking statements may be identified by words such as “will,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates” and similar expressions.

These statements are based on assumptions regarding government policy, continued interest in regulated neuroplastogen research, the availability of lawful development pathways, and the Company’s ability to maintain licenses, permits, supply arrangements and third-party relationships. These assumptions may prove incorrect. Risks and uncertainties that could cause actual results to differ materially include the possibility that the contemplated licensing or corporate arrangements are not completed on the terms or timetable expected; changes in law, regulation or enforcement priorities in the United States, Southern Africa or elsewhere; the continuing status of ibogaine as a controlled substance; clinical, regulatory and approval risks; competition and market adoption risks; financing risks; and the Company’s ability to maintain compliance with Nasdaq continued listing standards. This list is not exhaustive. These risks should be considered together with the risk factors described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to update such statements.

The Company makes no medical, treatment or health-benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved ibogaine or the Company’s other neuroplastogen compounds for therapeutic use, and their safety and efficacy have not been established through authorized clinical research. Rigorous scientific research and clinical trials are required. References to “GMP-compliant” mean production in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards and do not, by themselves, represent formal certification or approval by any regulatory authority unless expressly stated.

Learn more about the company at www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Biomedical Ltd.

Email: ir@psyencebiomed.com

Media Inquiries: media@psyencebiomed.com

General Information: info@psyencebiomed.com

Phone: +1 416-477-1708

Investor Contact:

Michael Kydd

Investor Relations Advisor

michael@psyencebiomed.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.